Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 9/20 | 0.57 |
| ▸ | TAAR1 | Q96RJ0 | 5/20 | 0.55 |
| ▸ | HTR2C | P28335 | 1/20 | 0.55 |
| ▸ | HMGCR | P04035 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3469319 | 0.90 | HMGCR (0.60) | HTR2ATAAR1HTR2CHMGCRSMN1; SMN2 | |
| SCHEMBL25513088 | 0.88 | HTR2A (0.72) | HTR2ATAAR1HTR2CHMGCR | |
| SCHEMBL31520294 | 0.88 | HTR2A (0.72) | HTR2ATAAR1HTR2CHMGCR | |
| SCHEMBL30136435 | 0.83 | HMGCR (0.67) | HTR2ATAAR1HTR2CHMGCR | |
| SCHEMBL2496360 | 0.83 | HMGCR (0.67) | HTR2ATAAR1HTR2CHMGCR | |
| SCHEMBL28748249 | 0.83 | HMGCR (0.67) | HTR2ATAAR1HTR2CHMGCR | |
| SCHEMBL26707584 | 0.82 | HMGCR (0.37) | HTR2ATAAR1HTR2CHMGCRSMN1; SMN2 | |
| SCHEMBL12892627 | 0.81 | TAAR1 (0.70) | HTR2ATAAR1HTR2CHMGCR | |
| SCHEMBL14581261 | 0.81 | SMN1; SMN2 (0.47) | HTR2ATAAR1HTR2CHMGCRSMN1; SMN2 | |
| SCHEMBL26080665 | 0.80 | HTR2A (0.56) | HTR2ATAAR1HTR2CHMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050159465-A1 | 3-(4-Hydroxy-2-methylphenyl)-1,2-benzisoxazol-6-ol; estrogen receptor modulators; ability to compete with 17 beta -estradiol for both Estrogen Receptor alpha and Estrogen Receptor beta; Estrogen Receptor Selective Agonist Antagonist activity; anticancer, antiinflammatory, anticholesterol | WYETH (US) | 2005-07-21 | — | — | US | disclosed |
| US-6884814-B2 | Phenyl benzisoxazoles as estrogenic agents | WYETH (US) | 2005-04-26 | — | — | US | disclosed |
| US-20030207927-A1 | Phenyl benzisoxazoles as estrogenic agents | WYETH | 2003-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207927-A1 | Phenyl benzisoxazoles as estrogenic agents | ESR1, ESR2, GPER1 | HTR2A 981/4885TAAR1 2445/4885HTR2C 386/4885 |
| US-20050159465-A1 | 3-(4-Hydroxy-2-methylphenyl)-1,2-benzisoxazol-6-ol; estrogen receptor modulators; ability to compete with 17 beta -estradiol for both Estrogen Receptor alpha and Estrogen Receptor beta; Estrogen Receptor Selective Agonist Antagonist activity; anticancer, antiinflammatory, anticholesterol | ESR2, ESR1, GPER1 | HTR2A 890/4885TAAR1 1562/4885HTR2C 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.